Tomosada Yoshikawa
Direttore/Membro del Consiglio presso KLAB INC.
Profilo
Tomosada Yoshikawa is an Independent Outside Director at KLab, Inc. since 2018.
He is also a Director & Vice President at SUS Co., Ltd.
since 2018 and a Director at Cross Reality Co., Ltd.
since 2019.
Previously, he served as an Independent Outside Director at tella, Inc. from 2018 to 2019 and as MD, Head-Administration & IR Contact at Taiko Pharmaceutical Co., Ltd.
from 2009 to 2013.
He holds an MBA from Babson College (1999) and an undergraduate degree from Kwansei Gakuin University (1989).
Posizioni attive di Tomosada Yoshikawa
| Società | Posizione | Inizio |
|---|---|---|
| KLAB INC. | Direttore/Membro del Consiglio | 25/03/2018 |
| SUS CO.,LTD. | Direttore/Membro del Consiglio | 01/12/2018 |
| Cross Reality Co., Ltd. | Direttore/Membro del Consiglio | 01/09/2019 |
Precedenti posizioni note di Tomosada Yoshikawa
| Società | Posizione | Fine |
|---|---|---|
| TELLA, INC. | Direttore/Membro del Consiglio | 27/03/2019 |
| TAIKO PHARMACEUTICAL CO.,LTD. | Direttore Finanziario/CFO | 01/06/2013 |
Formazione di Tomosada Yoshikawa
| Babson College | Masters Business Admin |
| Kwansei Gakuin University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| KLAB INC. | Technology Services |
| SUS CO.,LTD. | Commercial Services |
| TAIKO PHARMACEUTICAL CO.,LTD. | Health Technology |
| Aziende private | 2 |
|---|---|
| Cross Reality Co., Ltd. | |
tella, Inc.
 tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
- Borsa valori
- Insiders
- Tomosada Yoshikawa
